Harmony Biosciences (HRMY) Tops Q2 EPS by $1.05, provides guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $1.05. Revenue for the quarter came in at $172.8 million versus the consensus estimate of $173.24 million.

GUIDANCE:

Harmony Biosciences sees FY2024 revenue of $700-720 million, versus the consensus of $709.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Midera Food Processing and Centrus Energy to join S&P SmallCap 600
• Trump plans to pursue removal of Fed Governor Lisa Cook after court ruling - CNBC interview